New drug candidates show promise for cure for Chagas disease

A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.

Chagas disease or American trypanosomiasis, caused by Trypanosoma cruzi, affects about 18 million people living mostly in Latin America. The parasite is transmitted to humans by blood-sucking reduviid bugs, also known as kissing bugs due to their predilection for feeding on the faces of their victims. In the United States, Chagas disease is considered one of the neglected parasitic infections, a group of five parasitic diseases that have been targeted by CDC for action.

"While historically infection was largely confined to poor and rural populations in Central and South America, it has been emerging in the U.S., Canada, Europe, Japan, and Australia, due to immigration, and nonvectorial transmission is becoming a ," says Deborah Nicoll-Griffith of the Merck Frosst Centre for Therapeutic Research in Kirkland, Quebec, a researcher on the study. One 2005 estimate put the number of people infected within the U.S. at 300,000 (1/1000).

There are two phases of Chagas disease: the acute phase and the chronic phase. Both phases can be symptom free or life threatening. Left untreated the disease can lead to cardiac and digestive disorders, as the parasite burrows into the heart, esophagus and colon tissue where it causes damage over time.

The current standard of care, the drug benznidazole, has significant activity against the parasite during the acute phase, but is less effective once the disease becomes chronic.

Efforts to find new drugs focus on disrupting an enzyme, cruzipain, which the parasite uses for digestion, to produce other cellular machinery, to evade the host's immune system, and to invade heart and gastrointestinal tissues.

Nicoll-Griffith and her colleagues identified two compounds known as reversible cysteine protease inhibitors that fit cruzipain like jigsaw puzzle pieces, jamming the enzyme. In the study, they tested the efficacy of the compounds in mice against that of benznidazole. While all treatment groups showed a marked reduction in parasite burden, in all tissues, the two experimental compounds had greater cure rates of acute infections (90% and 78%) compared to benznidazole (71%.)

"The efficacy shown in these T. cruzi murine studies suggests that nitrile-containing cruzipain inhibitors show promise as a viable approach for a safe and effective treatment of Chagas disease," write the researchers.

More information: www.asm.org/images/Communicati… /2013/1213chagas.pdf

Related Stories

Cure in sight for kissing bug's bite

Feb 14, 2013

Chagas disease, a deadly tropical infection caused by the protozoan parasite Trypanosoma cruzi and transmitted by biting insects called "kissing bugs," has begun to spread around the world, including the U.S. Yet current treatm ...

Recommended for you

US warns Ebola could infect 1.4 million by 2015

1 hour ago

The number of Ebola infections in Liberia and Sierra Leone could skyrocket to 1.4 million by January 2015, according to a worst-case scenario released by US health authorities Tuesday.

Team finds method for more precise diagnosis of pneumonia

2 hours ago

A patient survives life-threatening trauma, is intubated in the intensive care unit (ICU) to support his or her affected vital functions, starts to recover, and then develops pneumonia. It's a scenario well-known to physicians, ...

Screen women for chlamydia, gonorrhea, experts say

3 hours ago

(HealthDay)—All sexually active women should be screened for two of the most common sexually transmitted infections: chlamydia and gonorrhea, according to new recommendations from the U.S. Preventive Services ...

Noninvasive devices may help migraines, FDA says

4 hours ago

(HealthDay)—Two new prescription devices approved by the U.S. Food and Drug Administration (FDA) may provide some relief for people with migraine headaches who don't tolerate migraine medications well, ...

User comments